Molecule News and Research

RSS

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

U of A study looks at Bim molecule to understand autoimmune diseases

Understanding why immune cells, called T-cells, attack the body is vital in the war against autoimmune diseases like diabetes. University of Alberta researcher Troy Baldwin is a step closer to understanding why the body's T-cells sometimes attack healthy cells causing autoimmune diseases.

7 Mar 2012

VBC files patent applications related to beneficial health effects of S-ABA

Valent BioSciences Corporation announced today it has filed worldwide patent applications claiming beneficial health effects of abscisic acid (S-ABA) in humans and animals. S-ABA is a naturally occurring substance found in all plants, including fruits and vegetables.

7 Mar 2012

Pten gene can also fight against obesity, ageing process

This result, obtained after five years' research, is published in leading journal Cell Metabolism. The authors, led by Manuel Serrano (CNIO), believe it will open the door to new therapeutic options not only against cancer, but against obesity and even the ageing process.

7 Mar 2012

Scripps scientists to develop new generation of broad spectrum anti-cancer therapeutics

A pair of Scripps Research Institute scientists, one a cancer biologist and the other a chemist, has been awarded $3.85 million from the National Institutes of Health (NIH) to develop a new generation of broad spectrum anti-cancer therapeutics, including breast cancer and lymphoma.

6 Mar 2012

Penn-led team develops universal approach to personalized cancer therapy based on T cells

Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first time a system for making an adaptable, engineered T-cell to attack specific tumor types has been proposed, depending on which abnormal proteins, called antigens, are expressed by individual patients' tumor cells.

6 Mar 2012

Cdk1 molecule plays an important role in mammalian egg maturation

Women who have eggs that cannot mature will not become pregnant, and they cannot be helped by in vitro fertilization (IVF). Now researchers at the University of Gothenburg, Sweden, have identified a molecule called Cdk1 that has an important function for mammalian egg maturation. In the future this could lead to an increased rate of successful IVF.

6 Mar 2012

Astex fourth quarter total revenues increase to $21.2 million

Astex Pharmaceuticals, Inc., today reported financial results for the fourth quarter and year ended December 31, 2011.

5 Mar 2012

MicroRNAs key to memory and learning process

Studying tiny bits of genetic material that control protein formation in the brain, Johns Hopkins scientists say they have new clues to how memories are made and how drugs might someday be used to stop disruptions in the process that lead to mental illness and brain wasting diseases.

5 Mar 2012

Certain microRNAs key to controlling actions of BDNF, linked to brain cell survival

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

SK Biopharmaceuticals' YKP3089 receives Korea Drug Development Fund

South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.

3 Mar 2012

REST molecule acts as an adapter in stem cells, times neuronal development

Upon fertilisation, a single cell is formed when egg and sperm fuse. Our entire body, with more than 200 specialised cell types and billions of cells are formed from this single cell. It is a scientific mystery how the early stem cells know what cell type to become, but a precise timing of the process is crucial for correct development and function of our body.

3 Mar 2012

Critical new details about structure of enterovirus 71

Researchers have discovered critical new details about the structure of a virus that causes potentially fatal brain swelling and paralysis in children, pointing toward designs for antiviral drugs to treat the disease.

3 Mar 2012

Scientists determine chemical features of DHPS enzyme's active site

More than 70 years after the first sulfa drugs helped to revolutionize medical care and save millions of lives, St. Jude Children's Research Hospital scientists have determined at an atomic level the mechanism these medications use to kill bacteria. The discovery provides the basis for a new generation of antibiotics that would likely be harder for bacteria to resist and cause fewer side effects.

2 Mar 2012

Combining two common cancer-fighting strategies may have 'tremendous synergy'

Researchers at the University of Illinois at Chicago College of Medicine have found that a molecule found at elevated levels in cancer cells seems to protect them from the "cell-suicide" that is usually triggered by chemotherapy or radiation.

2 Mar 2012

Conference on follow-on versions of complex drugs

On March 9, the New York Academy of Sciences will present "Scientific Considerations for Complex Drugs in Light of Established Regulatory Guidance." This full-day conference will explore current definitions, global scientific and regulatory hurdles, and future challenges for follow-on versions of complex drugs.

2 Mar 2012

New HS44 molecule inhibits lung metastasis

One type of white blood cell, the Natural Killer T Cells, fights against infections and tumours by freeing cytokine proteins which activate the body's immune response and destroy infected or malignant cells. To do so they must receive an activation signal. Specific receptors located on their surface act as switches: they activate the lymphocyte in presence of an antigen, a molecule which triggers alarm signals.

2 Mar 2012

New method for creating nanofibers could improve drug delivery methods

A new method for creating nanofibers made of proteins, developed by researchers at Polytechnic Institute of New York University (NYU-Poly), promises to greatly improve drug delivery methods for the treatment of cancers, heart disorders and Alzheimer's disease, as well as aid in the regeneration of human tissue, bone and cartilage.

1 Mar 2012